<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Bioinformatics</journal-id>
    <journal-title-group>
      <journal-title>BMC Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1471-2105</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">5217312</article-id>
    <article-id pub-id-type="publisher-id">1433</article-id>
    <article-id pub-id-type="doi">10.1186/s12859-016-1433-7</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Software</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>KinMap: a web-based tool for interactive navigation through human kinome data</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4689-6354</contrib-id>
        <name>
          <surname>Eid</surname>
          <given-names>Sameh</given-names>
        </name>
        <address>
          <email>eid@bio.mx</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Turk</surname>
          <given-names>Samo</given-names>
        </name>
        <address>
          <email>turk@bio.mx</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Volkamer</surname>
          <given-names>Andrea</given-names>
        </name>
        <address>
          <email>volkamer@bio.mx</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Rippmann</surname>
          <given-names>Friedrich</given-names>
        </name>
        <address>
          <email>friedrich.rippmann@merckgroup.com</email>
        </address>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <name>
          <surname>Fulle</surname>
          <given-names>Simone</given-names>
        </name>
        <address>
          <email>fulle@bio.mx</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <aff id="Aff1"><label>1</label>BioMed X Innovation Center, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany </aff>
      <aff id="Aff2"><label>2</label>Computational Chemistry and Biology, Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>5</day>
      <month>1</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>5</day>
      <month>1</month>
      <year>2017</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2017</year>
    </pub-date>
    <volume>18</volume>
    <elocation-id>16</elocation-id>
    <history>
      <date date-type="received">
        <day>18</day>
        <month>4</month>
        <year>2016</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>12</month>
        <year>2016</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s). 2017</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p>Annotations of the phylogenetic tree of the human kinome is an intuitive way to visualize compound profiling data, structural features of kinases or functional relationships within this important class of proteins. The increasing volume and complexity of kinase-related data underlines the need for a tool that enables complex queries pertaining to kinase disease involvement and potential therapeutic uses of kinase inhibitors.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p>Here, we present KinMap, a user-friendly online tool that facilitates the interactive navigation through kinase knowledge by linking biochemical, structural, and disease association data to the human kinome tree. To this end, preprocessed data from freely-available sources, such as ChEMBL, the Protein Data Bank, and the Center for Therapeutic Target Validation platform are integrated into KinMap and can easily be complemented by proprietary data. The value of KinMap will be exemplarily demonstrated for uncovering new therapeutic indications of known kinase inhibitors and for prioritizing kinases for drug development efforts.</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p>KinMap represents a new generation of kinome tree viewers which facilitates interactive exploration of the human kinome. KinMap enables generation of high-quality annotated images of the human kinome tree as well as exchange of kinome-related data in scientific communications. Furthermore, KinMap supports multiple input and output formats and recognizes alternative kinase names and links them to a unified naming scheme, which makes it a useful tool across different disciplines and applications. A web-service of KinMap is freely available at <ext-link ext-link-type="uri" xlink:href="http://www.kinhub.org/kinmap/">http://www.kinhub.org/kinmap/</ext-link>.</p>
      </sec>
      <sec>
        <title>Electronic supplementary material</title>
        <p>The online version of this article (doi:10.1186/s12859-016-1433-7) contains supplementary material, which is available to authorized users.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Protein kinases</kwd>
      <kwd>Human kinome tree</kwd>
      <kwd>Interactive annotation</kwd>
      <kwd>Images</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2017</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1" sec-type="introduction">
    <title>Background</title>
    <p>Protein kinases are key effectors in the intracellular signal transduction pathways and, when dysregulated by mutations or overexpression, can cause the progression of diseases such as cancer and inflammation [<xref ref-type="bibr" rid="CR1">1</xref>]. Since the clinical success of Gleevec (imatinib) in the treatment of chronic myeloid leukemia [<xref ref-type="bibr" rid="CR2">2</xref>], protein kinases have become among the most pursued drug targets for cancer. The human kinome comprises nearly 540 kinases which were initially classified by Manning et al. based on the underlying sequences into eight typical groups (AGC, CAMK, CK1, CMGC, STE, TK, TKL, Other) and 13 atypical families [<xref ref-type="bibr" rid="CR3">3</xref>]. The resulting phylogenetic tree is commonly used to visualize compound profiling data [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] or structural features of kinases [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. A continuously growing body of knowledge is available, covering not only structural and biochemical aspects but also data related to diseases and genetic modifications. Hence, a tool that integrates kinome-related data from multiple resources would allow exploration of complex queries pertaining to kinase involvement in the pathophysiology of various disorders as well as to the disease-modulating potential of protein kinase inhibitors. To date, a few kinome tree viewers have been developed to facilitate visualization tasks such as the TREEspot tool from DiscoveRx [<xref ref-type="bibr" rid="CR8">8</xref>], the NCGC Kinome Viewer [<xref ref-type="bibr" rid="CR9">9</xref>], and Kinome Render [<xref ref-type="bibr" rid="CR10">10</xref>]. The former two were primarily designed for the visualization of compound profiling data but they do not allow the annotation of further information in a straightforward manner. Kinome Render offers a wider variety of annotation formats and customizable text labels, but it requires a specialized input file format and does not accept input from commonly used formats such as spreadsheets. Moreover, Kinome Render only creates static images and does not allow interactive linking to other kinome-related resources. The mentioned limitations of already existing kinome tree viewers motivated us to develop KinMap.</p>
    <p>KinMapis a web-based tool for creating interactive annotations of the phylogenetic tree of the human kinome and facilitating navigation through kinase-related data such as the number of available PDB structures, number of compound data in ChEMBL, inhibitor profiling data sets, kinase disease associations, as well as proprietary data. The online tool supports various input and output formats (e.g. spreadsheets), recognizes alternative kinase naming schemes and produces high-resolution images. Finally, KinMap employs modern web technologies to run entirely locally in the web browser without uploading sensitive data to a server. The key features of KinMap are summarized in Fig. <xref rid="Fig1" ref-type="fig">1a</xref> and discussed in detail below.<fig id="Fig1"><label>Fig. 1</label><caption><p>The KinMap web interface. <bold>a</bold> Summary of the key features. <bold>b</bold> Navigation panel which allows linking kinome related data sources, e.g. non-small cell lung carcinoma from CTTV (<italic>green triangles</italic>). <bold>c</bold> Preview of the built-in spreadsheet editor showing inhibition profile of erlotinib (<italic>red circles</italic> on the tree) [<xref ref-type="bibr" rid="CR4">4</xref>]; auto-complete functions (<italic>blue rectangles</italic>) facilitate kinase selection and style modification. Annotation sizes can be automatically rescaled based on bioactivity data (<italic>red rectangles</italic>) or other input values in the spreadsheet. <bold>d</bold> Kinase name suggestions in case of incomplete or ambiguous names in the input. <bold>e</bold> Supported output formats CSV: comma-separated values; PNG: Portable Network Graphics; SVG: Scalable Vector Graphics; XML: extensible markup language; KMAP: native KinMap format. A box showing detailed information for the ABL1 kinase illustrates the interactive view mode</p></caption><graphic xlink:href="12859_2016_1433_Fig1_HTML" id="MO1"/></fig>
</p>
  </sec>
  <sec id="Sec2">
    <title>Implementation</title>
    <sec id="Sec3">
      <title>Kinome navigation via precompiled data sources</title>
      <p>To facilitate the exploration of kinase-related information, structural, biochemical, and functional data were extracted from external resources and integrated into KinMap. Briefly: the number of kinase structures were obtained from the Protein Data Bank [<xref ref-type="bibr" rid="CR11">11</xref>], the number of assay and compound values from ChEMBL [<xref ref-type="bibr" rid="CR12">12</xref>], inhibition profiles from published panels [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], and information related to kinase-disease associations from the Center for Therapeutic Target Validation (CTTV) platform [<xref ref-type="bibr" rid="CR14">14</xref>]. The current version of these data sources can be found online at <ext-link ext-link-type="uri" xlink:href="http://www.kinhub/kinmap/help-sources.html">http://www.kinhub/kinmap/help-sources.html</ext-link>. In the case of the CTTV data, entries with low association scores (&lt;0.1) were excluded, while only disease associations linked to one or more of the following evidence types were kept: genetic, somatic mutations, drugs, affected pathways or RNA expression [<xref ref-type="bibr" rid="CR14">14</xref>]. Eventually, this allows the user to visually investigate kinase involvement in more than 670 diseases across 16 therapeutic areas.</p>
      <p>A specialized <italic>navigation mode</italic> in KinMap allows interactive exploration of the relationships between these data sources. Annotations can be added to the tree directly from the built-in data sources, individually styled, and interactively resized using relevant metrics such as inhibition constants. Figure <xref rid="Fig1" ref-type="fig">1</xref> outlines the key features of KinMap and illustrates the combined annotations of the inhibition profile of erlotinib [<xref ref-type="bibr" rid="CR4">4</xref>] and kinases associated with non-small cell lung carcinoma [<xref ref-type="bibr" rid="CR14">14</xref>]. The annotated tree in Fig. <xref rid="Fig1" ref-type="fig">1</xref> exemplifies the identification of key targets, e.g. EGFR and ABL1, responsible for the therapeutic action of erlotinib.</p>
    </sec>
    <sec id="Sec4">
      <title>Data input formats</title>
      <p>In addition to the precompiled data sources, users can create customized annotations in KinMap by using various input formats ranging from a simple list of kinases to complex spreadsheets and by adjusting the styles, sizes, and text labels on the fly. KinMap features an interactive spreadsheet editor which enables the user to import annotations from spreadsheets, to add or delete annotations, and to modify annotations styles and sizes. Drop-down menus with auto-complete functions increase the convenience of adjusting annotations in the spreadsheet editor. Moreover, KinMap can read additional data from CSV input files, e.g. bioactivity values, whereby the user can readjust annotation sizes using the automated rescaling function in the spreadsheet editor (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>). Additional data can also serve as information sources for the interactive kinome view (discussed below). Finally, KinMap supports a minimalistic text input for less sophisticated annotations. For example, the following concise syntax annotates eight kinases potentially involved in cardiomyopathy [<xref ref-type="bibr" rid="CR15">15</xref>]:</p>
      <p>The first line defines the annotation style of the succeeding kinases until another assignment is specified. In the present example, kinases are marked as squares that are 25 × 25 pixels in size, colored in red, and surrounded by a grey border.</p>
    </sec>
    <sec id="Sec5">
      <title>Kinase names</title>
      <p>Different naming schemes and abbreviations of kinases are used by researchers across different groups and/or disciplines. To account for this, KinMap contains a versatile parsing function that links commonly used kinase names to a unified naming scheme. The current parsing function recognizes names used by Manning [<xref ref-type="bibr" rid="CR3">3</xref>], recommended by the UniProt Consortium [<xref ref-type="bibr" rid="CR16">16</xref>], approved by the HUGO Gene Nomenclature Committee [<xref ref-type="bibr" rid="CR17">17</xref>], as well as any of the alternative names listed in these resources. Moreover, the parsing function accepts incomplete or ambiguous kinase names and allows the user to select the intended kinase from a prioritized list of potential matches in a specialized interface (Fig. <xref rid="Fig1" ref-type="fig">1d</xref>).</p>
    </sec>
    <sec id="Sec6">
      <title>Visualization and interactive kinome view</title>
      <p>KinMap can be used to produce sophisticated kinome tree annotations integrating information from multiple sources. The increasing availability and complexity of kinase-related information can easily result in cluttered kinome tree annotations that might be hard to grasp. Therefore, we implemented additional visualization options in KinMap to maximize the usability of the annotated kinome tree, e.g. zoom and drag the view, customize text labels, and toggle tree components on and off. In addition, KinMap introduces an interactive mode providing a hovering function which can display detailed information for a particular kinase such as inhibition assay results (e.g. ABL1 in Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The interactive view is particularly useful for browsing and sharing complex data without overloading the information content of the annotated kinome tree.</p>
    </sec>
    <sec id="Sec7">
      <title>Output formats and data exchange</title>
      <p>KinMap allows exporting annotated maps to <italic>static</italic> high-quality images (PNG and SVG), e.g. for use in journal publications and posters. Additionally, KinMap supports three <italic>editable</italic> file formats: plain text (TXT), comma-separated values (CSV), extensible markup language (XML), and native KinMap (KMAP) format. The minimalistic plain text format (see example above) saves lists of kinases and concise style directives making it suitable for highlighting distinct subsets of kinases by different annotation styles. The CSV format is more expansive and can be modified using text editors or spreadsheet software, e.g. Microsoft Excel, to facilitate data exchange. Finally, the native KMAP format preserves the metadata required to exactly reproduce the view of KinMap, e.g. label font settings, zoom level, and interactive mode settings.</p>
    </sec>
  </sec>
  <sec id="Sec8" sec-type="discussion">
    <title>Results and discussion</title>
    <p>KinMap facilitates visualization of data from different resources such as structural, biochemical, and functional data, and allows not only generation of high-quality pictures but also interactive exploration of connections. The navigation possibilities will be now exemplarily demonstrated in two test cases (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The first one aims to identify new therapeutic applications for known kinase inhibitors and the second one to prioritize kinases for drug development projects. Instructions to produce these illustrations are available in online tutorials at <ext-link ext-link-type="uri" xlink:href="http://www.kinhub/kinmap/tutorial.html">http://www.kinhub/kinmap/tutorial.html</ext-link> and the corresponding input files are provided in the Additional file <xref rid="MOESM1" ref-type="media">1</xref>.<fig id="Fig2"><label>Fig. 2</label><caption><p>Examples of kinome tree annotation created by KinMap. <bold>a</bold> Inhibition profiles of two approved drugs sorafenib (<italic>orange circles</italic>) and sunitinib (<italic>creme circles</italic>) [<xref ref-type="bibr" rid="CR4">4</xref>], and kinases linked to thyroid carcinoma (<italic>blue squares</italic>) and colonic neoplasm (<italic>red squares</italic>) as extracted from the CTTV platform [<xref ref-type="bibr" rid="CR14">14</xref>]. <bold>b</bold> Availability of structural and bioactivity data for the human kinome; <italic>red circles</italic>: number of structures per kinase in the PDB [<xref ref-type="bibr" rid="CR11">11</xref>]; <italic>blue circles</italic>: number of activity measurements for the respective kinase in ChEMBL [<xref ref-type="bibr" rid="CR12">12</xref>]; <italic>green triangles</italic>: key targets of clinically approved kinase inhibitors [<xref ref-type="bibr" rid="CR12">12</xref>]</p></caption><graphic xlink:href="12859_2016_1433_Fig2_HTML" id="MO3"/></fig>
</p>
    <sec id="Sec9">
      <title>Exploring novel therapeutic indications</title>
      <p>Over the past few decades the development costs for new drugs has increased dramatically, but this was paradoxically accompanied by a decline in the likelihood of approval in the clinical testing phases [<xref ref-type="bibr" rid="CR18">18</xref>]. However, clinically approved drugs and investigational drugs that fail due to lack of efficacy or economic reasons could still be leveraged to find new indications, a process referred to as drug repurposing. This approach is economically appealing as these drugs have already passed the expensive early phases of clinical testing and have demonstrated good safety profiles and, therefore, have lower chances of subsequent clinical failure [<xref ref-type="bibr" rid="CR19">19</xref>]. Exploring novel indications is particularly valuable in the case of anti-neoplastic kinase inhibitors due to the lower phase 1 success rate of oncology drugs (6.7%) compared to other indications [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
      <p>Figure <xref rid="Fig2" ref-type="fig">2a</xref> shows the inhibition profile of two clinically approved kinase inhibitors, sorafenib and sunitinib, against a panel of 317 protein kinases [<xref ref-type="bibr" rid="CR4">4</xref>]. Sorafenib inhibits several tyrosine protein kinases, such as VEGFR, PDGFR and Raf family kinases. It was initially approved by the FDA for the treatment of patients with advanced renal cancer in 2005 [<xref ref-type="bibr" rid="CR20">20</xref>], and later also for hepatocellular carcinoma [<xref ref-type="bibr" rid="CR21">21</xref>]. Sunitinib inhibits a number of receptor tyrosine protein kinases including PDGFR (alpha and beta), VEGFR2 (KDR), KIT, FLT3 and RET, which are key factors in tumorigenesis and neoplastic cell proliferation [<xref ref-type="bibr" rid="CR22">22</xref>]. In 2006, sunitinib was approved by the FDA as a treatment for gastrointestinal stromal tumors and renal carcinoma as well as for a rare type of pancreatic cancer in 2011. Additionally, Fig. <xref rid="Fig2" ref-type="fig">2a</xref> shows the kinases associated with two types of cancers for which both drugs have not been initially approved: thyroid and colon carcinomas [<xref ref-type="bibr" rid="CR14">14</xref>]. The overlap between several key targets of sorafenib and sunitinib, and kinases implicated in thyroid and colon carcinomas indicates that the two compounds are promising candidates for treatment of both cancer types. Interestingly, a 2010 study of off-label use of both drugs demonstrated the efficacy in patients with widely metastatic, progressive differentiated thyroid cancer [<xref ref-type="bibr" rid="CR23">23</xref>]. Subsequently, sorafenib was approved by the FDA for the treatment of metastatic differentiated thyroid cancer in 2013, while sunitinib is currently in phase 2 clinical trial as an adjunctive treatment for advanced differentiated thyroid cancer [<xref ref-type="bibr" rid="CR24">24</xref>]. Moreover, off-label use of sorafenib showed positive results in personalized colon cancer therapy in a number of cases: e.g. combining sorafenib with cetuximab and panitumumab resulted in a notably long period of progression-free survival in a patient with V600E BRAF-mutant colon cancer [<xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, a metastatic colorectal cancer patient with FLT3 mutation showed significant symptomatic and laboratory improvement with sorafenib treatment [<xref ref-type="bibr" rid="CR26">26</xref>]. In line with these examples, KinMap facilitates combining biochemical and disease pathology information which can help uncover potential therapeutic indications of known kinase inhibitors.</p>
    </sec>
    <sec id="Sec10">
      <title>Structure and bioactivity data</title>
      <p>Current structural and biochemical coverage of the human kinome as well as the distribution of primary targets of clinically approved inhibitors are shown in Fig. <xref rid="Fig2" ref-type="fig">2b</xref>, revealing some interesting insights. Firstly, most of the kinases targeted by approved drugs (green triangles) are located in the TK and TKL groups, leaving ample therapeutic opportunities for drug development against clinically relevant kinases in other groups. Secondly, nearly 200 kinases lack any experimental structures (red circles) in the PDB [<xref ref-type="bibr" rid="CR11">11</xref>] despite having abundant biochemical assay results (blue circles). For instance, the dual specificity protein kinase CLK4 and the RAC-gamma serine/threonine-protein kinase AKT3 have more than 2000 activity values in ChEMBL, but lack PDB structures and were so far not considered as key targets in drug development projects. Interestingly, down-regulation of AKT3 was shown to inhibit tumor growth in mouse xenograft models, providing a new treatment option for the intractable triple-negative breast cancer [<xref ref-type="bibr" rid="CR27">27</xref>]. On the other hand, CLK4 plays a key role in controlling the function of the spliceosome and could be modulated to rectify splicing abnormalities in several diseases including cancer [<xref ref-type="bibr" rid="CR28">28</xref>]. Due to their potential value in targeting oncogenesis [<xref ref-type="bibr" rid="CR29">29</xref>], elucidating their 3D structures would provide a competitive advantage by guiding the rational development of novel inhibitors. Finally, highlighting under-investigated kinases can be combined with other kinome studies, e.g. druggability assessment [<xref ref-type="bibr" rid="CR6">6</xref>], to provide directions for future drug development efforts.</p>
    </sec>
  </sec>
  <sec id="Sec11" sec-type="conclusion">
    <title>Conclusions</title>
    <p>Annotations of the phylogenetic tree of the human kinome is an intuitive way to visualize and navigate through the continuously growing knowledge in the protein kinase field such as the number of PDB structures, compound data or kinase disease associations. The analysis options for the different data sources are manifold and include keeping track of drug development projects, repurposing clinically approved kinase inhibitors, or uncovering potential new drug targets. KinMap facilitates such analysis by providing an interactive kinome tree viewer that not only allows generating annotated images and sharing data, but also provides a user-friendly interface to explore data from different sources. The key concepts of KinMap have been described here along with two examples for using the navigation feature to search for new therapeutic indications of two known kinase inhibitors and to investigate the available structural and biochemical data on human kinases. We will continually update the built-in resources and welcome suggestions to integrate additional sources into KinMap.</p>
  </sec>
</body>
<back>
  <app-group>
    <app id="App1">
      <sec id="Sec12">
        <title>Additional file</title>
        <p>
          <media position="anchor" xlink:href="12859_2016_1433_MOESM1_ESM.zip" id="MOESM1">
            <label>Additional file 1:</label>
            <caption>
              <p>(KinMap_Examples.zip) contains the input CSV files used to generate the annotated kinome trees in Fig. <xref rid="Fig1" ref-type="fig">1</xref> (Example_1_Erlotinib_NSCLC.csv), Fig. <xref rid="Fig2" ref-type="fig">2a</xref> (Example_2_Sunitinib_Sorafenib_Cancer.csv), and Fig. <xref rid="Fig2" ref-type="fig">2b</xref> (Example_3_Kinase_Stats.csv). (ZIP 5 kb)</p>
            </caption>
          </media>
        </p>
      </sec>
    </app>
  </app-group>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>CSV</term>
        <def>
          <p>Comma-separated values</p>
        </def>
      </def-item>
      <def-item>
        <term>CTTV</term>
        <def>
          <p>Center for Therapeutic Target Validation</p>
        </def>
      </def-item>
      <def-item>
        <term>KMAP</term>
        <def>
          <p>Native KinMap format</p>
        </def>
      </def-item>
      <def-item>
        <term>PDB</term>
        <def>
          <p>Protein Data Bank</p>
        </def>
      </def-item>
      <def-item>
        <term>PNG</term>
        <def>
          <p>Portable Network Graphics</p>
        </def>
      </def-item>
      <def-item>
        <term>SVG</term>
        <def>
          <p>Scalable Vector Graphics</p>
        </def>
      </def-item>
      <def-item>
        <term>XML</term>
        <def>
          <p>Extensible markup language</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <ack>
    <title>Acknowledgements</title>
    <p>We thank Mireille Krier, Daniel Kuhn, and Paul Czodrowski for useful suggestions during the development of KinMap and Cell Signaling Technology, Inc. (<ext-link ext-link-type="uri" xlink:href="http://www.cellsignal.com">www.cellsignal.com</ext-link>) for the courtesy of reproducing the human kinome tree illustration.</p>
    <sec id="FPar1">
      <title>Funding</title>
      <p>The research of the “Selective Kinase Inhibitors” team at the BioMed X Innovation Center was kindly sponsored by Merck KGaA.</p>
    </sec>
    <sec id="FPar2">
      <title>Availability of data and materials</title>
      <p>A web-service of KinMap is freely available at <ext-link ext-link-type="uri" xlink:href="http://www.kinhub.org/kinmap/">http://www.kinhub.org/kinmap/</ext-link>. KinMap is a JavaScript-based web application and runs in common web browsers (platform-independent).</p>
    </sec>
    <sec id="FPar3">
      <title>Authors’ contributions</title>
      <p>SE designed and wrote the code for the KinMap web application, processed built-in data sources for interactive linking, and drafted the manuscript. ST and AV contributed to the curation and processing of the kinase-related data from ChEMBL and the kinase-disease association data. FR contributed to the planning of the web app layout and features as well as performing functionality testing and verification. SF envisioned the project, participated in its design and coordination and in drafting the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <sec id="FPar4">
      <title>Competing interests</title>
      <p>The web-service of KinMap is available free of charge to academic and commercial users. Commercial licenses for a custom version can be obtained upon request from the BioMed X Innovation Center. Please note that figures generated using KinMap shall be accompanied by the acknowledgement “Illustration reproduced courtesy of Cell Signaling Technology, Inc. (<ext-link ext-link-type="uri" xlink:href="http://www.cellsignal.com">www.cellsignal.com</ext-link>)”.</p>
    </sec>
    <sec id="FPar5">
      <title>Consent for publication</title>
      <p>Not applicable.</p>
    </sec>
    <sec id="FPar6">
      <title>Ethics approval and consent to participate</title>
      <p>Not applicable.</p>
    </sec>
  </ack>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="book">
        <person-group person-group-type="author">
          <name>
            <surname>Klebl</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Müller</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hamacher</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <source>Protein kinases as drug targets</source>
        <year>2011</year>
        <publisher-loc>Weinheim</publisher-loc>
        <publisher-name>Wiley-VCH</publisher-name>
        <fpage>49</fpage>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Druker</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Tamura</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Buchdunger</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ohno</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Segal</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Fanning</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zimmermann</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lydon</surname>
            <given-names>NB</given-names>
          </name>
        </person-group>
        <article-title>Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells</article-title>
        <source>Nat Med</source>
        <year>1996</year>
        <volume>2</volume>
        <issue>5</issue>
        <fpage>561</fpage>
        <lpage>6</lpage>
        <pub-id pub-id-type="doi">10.1038/nm0596-561</pub-id>
        <?supplied-pmid 8616716?>
        <pub-id pub-id-type="pmid">8616716</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Manning</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Whyte</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Martinez</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Sudarsanam</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>The protein kinase complement of the human genome</article-title>
        <source>Science</source>
        <year>2002</year>
        <volume>298</volume>
        <issue>5600</issue>
        <fpage>1912</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1126/science.1075762</pub-id>
        <?supplied-pmid 12471243?>
        <pub-id pub-id-type="pmid">12471243</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karaman</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Herrgard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Treiber</surname>
            <given-names>DK</given-names>
          </name>
          <name>
            <surname>Gallant</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Atteridge</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>KW</given-names>
          </name>
          <name>
            <surname>Ciceri</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Edeen</surname>
            <given-names>PT</given-names>
          </name>
          <name>
            <surname>Faraoni</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Floyd</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hunt</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Lockhart</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Milanov</surname>
            <given-names>ZV</given-names>
          </name>
          <name>
            <surname>Morrison</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Pallares</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>HK</given-names>
          </name>
          <name>
            <surname>Pritchard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wodicka</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Zarrinkar</surname>
            <given-names>PP</given-names>
          </name>
        </person-group>
        <article-title>A quantitative analysis of kinase inhibitor selectivity</article-title>
        <source>Nat Biotechnol</source>
        <year>2008</year>
        <volume>26</volume>
        <issue>1</issue>
        <fpage>127</fpage>
        <lpage>32</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt1358</pub-id>
        <?supplied-pmid 18183025?>
        <pub-id pub-id-type="pmid">18183025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Anastassiadis</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Deacon</surname>
            <given-names>SW</given-names>
          </name>
          <name>
            <surname>Devarajan</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ma</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Peterson</surname>
            <given-names>JR</given-names>
          </name>
        </person-group>
        <article-title>Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity</article-title>
        <source>Nat Biotechnol</source>
        <year>2011</year>
        <volume>29</volume>
        <issue>11</issue>
        <fpage>1039</fpage>
        <lpage>45</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.2017</pub-id>
        <?supplied-pmid 22037377?>
        <pub-id pub-id-type="pmid">22037377</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Volkamer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Eid</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Turk</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jaeger</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rippmann</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Fulle</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Pocketome of human kinases: prioritizing the ATP binding sites of (yet) untapped protein kinases for drug discovery</article-title>
        <source>J Chem Inf Model</source>
        <year>2015</year>
        <volume>55</volume>
        <issue>3</issue>
        <fpage>538</fpage>
        <lpage>49</lpage>
        <pub-id pub-id-type="doi">10.1021/ci500624s</pub-id>
        <?supplied-pmid 25557645?>
        <pub-id pub-id-type="pmid">25557645</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martin</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Mukherjee</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome</article-title>
        <source>J Chem Inf Model</source>
        <year>2012</year>
        <volume>52</volume>
        <issue>1</issue>
        <fpage>156</fpage>
        <lpage>70</lpage>
        <pub-id pub-id-type="doi">10.1021/ci200314j</pub-id>
        <?supplied-pmid 22133092?>
        <pub-id pub-id-type="pmid">22133092</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <mixed-citation publication-type="other">DiscoveRx Corporation Home Page. <ext-link ext-link-type="uri" xlink:href="http://www.discoverx.com/">http://www.discoverx.com/</ext-link>. Accessed 10 Apr 2016.</mixed-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <mixed-citation publication-type="other">The human kinome Java component. <ext-link ext-link-type="uri" xlink:href="http://tripod.nih.gov/?p=260">http://tripod.nih.gov/?p=260</ext-link>. Accessed 10 Apr 2016.</mixed-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chartier</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chénard</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Barker</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Najmanovich</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree</article-title>
        <source>Peer J</source>
        <year>2013</year>
        <volume>1</volume>
        <fpage>e126</fpage>
        <pub-id pub-id-type="doi">10.7717/peerj.126</pub-id>
        <?supplied-pmid 23940838?>
        <pub-id pub-id-type="pmid">23940838</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berman</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Westbrook</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Gilliland</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bhat</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Weissig</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shindyalov</surname>
            <given-names>IN</given-names>
          </name>
          <name>
            <surname>Bourne</surname>
            <given-names>PE</given-names>
          </name>
        </person-group>
        <article-title>The Protein Data Bank</article-title>
        <source>Nucleic Acids Res</source>
        <year>2000</year>
        <volume>28</volume>
        <issue>1</issue>
        <fpage>235</fpage>
        <lpage>42</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/28.1.235</pub-id>
        <?supplied-pmid 10592235?>
        <pub-id pub-id-type="pmid">10592235</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bento</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Gaulton</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hersey</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Bellis</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Chambers</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Davies</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Krüger</surname>
            <given-names>FA</given-names>
          </name>
          <name>
            <surname>Light</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Mak</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>McGlinchey</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nowotka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Papadatos</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Santos</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Overington</surname>
            <given-names>JP</given-names>
          </name>
        </person-group>
        <article-title>The ChEMBL bioactivity database: an update</article-title>
        <source>Nucleic Acids Res</source>
        <year>2014</year>
        <volume>42</volume>
        <issue>Database issue</issue>
        <fpage>D1083</fpage>
        <lpage>90</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkt1031</pub-id>
        <?supplied-pmid 24214965?>
        <pub-id pub-id-type="pmid">24214965</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Davis</surname>
            <given-names>MI</given-names>
          </name>
          <name>
            <surname>Hunt</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Herrgard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ciceri</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Wodicka</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Pallares</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Hocker</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Treiber</surname>
            <given-names>DK</given-names>
          </name>
          <name>
            <surname>Zarrinkar</surname>
            <given-names>PP</given-names>
          </name>
        </person-group>
        <article-title>Comprehensive analysis of kinase inhibitor selectivity</article-title>
        <source>Nat Biotechnol</source>
        <year>2011</year>
        <volume>29</volume>
        <issue>11</issue>
        <fpage>1046</fpage>
        <lpage>51</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.1990</pub-id>
        <?supplied-pmid 22037378?>
        <pub-id pub-id-type="pmid">22037378</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <mixed-citation publication-type="other">The CTTV Target Validation Platform. <ext-link ext-link-type="uri" xlink:href="http://www.targetvalidation.org">http://www.targetvalidation.org</ext-link>. Accessed 10 Apr 2016.</mixed-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dhalla</surname>
            <given-names>NS</given-names>
          </name>
          <name>
            <surname>Müller</surname>
            <given-names>AL</given-names>
          </name>
        </person-group>
        <article-title>Protein Kinases as Drug Development Targets for Heart Disease Therapy</article-title>
        <source>Pharm</source>
        <year>2010</year>
        <volume>3</volume>
        <issue>7</issue>
        <fpage>2111</fpage>
        <lpage>45</lpage>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>UniProt Consortium</collab>
        </person-group>
        <article-title>UniProt: a hub for protein information</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <issue>Database issue</issue>
        <fpage>D204</fpage>
        <lpage>12</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku989</pub-id>
        <pub-id pub-id-type="pmid">25348405</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gray</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Yates</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Seal</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>MW</given-names>
          </name>
          <name>
            <surname>Bruford</surname>
            <given-names>EA</given-names>
          </name>
        </person-group>
        <article-title>Genenames.org: the HGNC resources in 2015</article-title>
        <source>Nucleic Acids Res</source>
        <year>2015</year>
        <volume>43</volume>
        <issue>Database issue</issue>
        <fpage>D1079</fpage>
        <lpage>85</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gku1071</pub-id>
        <?supplied-pmid 25361968?>
        <pub-id pub-id-type="pmid">25361968</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hay</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Craighead</surname>
            <given-names>JL</given-names>
          </name>
          <name>
            <surname>Economides</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rosenthal</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Clinical development success rates for investigational drugs</article-title>
        <source>Nat Biotechnol</source>
        <year>2014</year>
        <volume>32</volume>
        <issue>1</issue>
        <fpage>40</fpage>
        <lpage>51</lpage>
        <pub-id pub-id-type="doi">10.1038/nbt.2786</pub-id>
        <?supplied-pmid 24406927?>
        <pub-id pub-id-type="pmid">24406927</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Oprea</surname>
            <given-names>TI</given-names>
          </name>
          <name>
            <surname>Mestres</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Drug repurposing: far beyond new targets for old drugs</article-title>
        <source>AAPS J</source>
        <year>2012</year>
        <volume>14</volume>
        <issue>4</issue>
        <fpage>759</fpage>
        <lpage>63</lpage>
        <pub-id pub-id-type="doi">10.1208/s12248-012-9390-1</pub-id>
        <?supplied-pmid 22826034?>
        <pub-id pub-id-type="pmid">22826034</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Escudier</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Eisen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Stadler</surname>
            <given-names>WM</given-names>
          </name>
          <name>
            <surname>Szczylik</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Oudard</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Siebels</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Negrier</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chevreau</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Solska</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Desai</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Rolland</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Demkow</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Hutson</surname>
            <given-names>TE</given-names>
          </name>
          <name>
            <surname>Gore</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Freeman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Shan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Simantov</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bukowski</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Group</surname>
            <given-names>TS</given-names>
          </name>
        </person-group>
        <article-title>Sorafenib in advanced clear-cell renal-cell carcinoma</article-title>
        <source>N Engl J Med</source>
        <year>2007</year>
        <volume>356</volume>
        <issue>2</issue>
        <fpage>125</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJMoa060655</pub-id>
        <?supplied-pmid 17215530?>
        <pub-id pub-id-type="pmid">17215530</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Keating</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Santoro</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Sorafenib: a review of its use in advanced hepatocellular carcinoma</article-title>
        <source>Drugs</source>
        <year>2009</year>
        <volume>69</volume>
        <issue>2</issue>
        <fpage>223</fpage>
        <lpage>40</lpage>
        <pub-id pub-id-type="doi">10.2165/00003495-200969020-00006</pub-id>
        <?supplied-pmid 19228077?>
        <pub-id pub-id-type="pmid">19228077</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gan</surname>
            <given-names>HK</given-names>
          </name>
          <name>
            <surname>Seruga</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Knox</surname>
            <given-names>JJ</given-names>
          </name>
        </person-group>
        <article-title>Sunitinib in solid tumors</article-title>
        <source>Expert Opin Investig Drugs</source>
        <year>2009</year>
        <volume>18</volume>
        <issue>6</issue>
        <fpage>821</fpage>
        <lpage>34</lpage>
        <pub-id pub-id-type="doi">10.1517/13543780902980171</pub-id>
        <?supplied-pmid 19453268?>
        <pub-id pub-id-type="pmid">19453268</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cabanillas</surname>
            <given-names>ME</given-names>
          </name>
          <name>
            <surname>Waguespack</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Bronstein</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Williams</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hernandez</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lopez</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sherman</surname>
            <given-names>SI</given-names>
          </name>
          <name>
            <surname>Busaidy</surname>
            <given-names>NL</given-names>
          </name>
        </person-group>
        <article-title>Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience</article-title>
        <source>J Clin Endocrinol Metab</source>
        <year>2010</year>
        <volume>95</volume>
        <issue>6</issue>
        <fpage>2588</fpage>
        <lpage>95</lpage>
        <pub-id pub-id-type="doi">10.1210/jc.2009-1923</pub-id>
        <?supplied-pmid 20392874?>
        <pub-id pub-id-type="pmid">20392874</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bikas</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kundra</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Desale</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mete</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>O’Keefe</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>BG</given-names>
          </name>
          <name>
            <surname>Wray</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gandhi</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Barett</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Jelinek</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Wexler</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Wartofsky</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Burman</surname>
            <given-names>KD</given-names>
          </name>
        </person-group>
        <article-title>Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer</article-title>
        <source>Eur J Endocrinol</source>
        <year>2016</year>
        <volume>174</volume>
        <issue>3</issue>
        <fpage>373</fpage>
        <lpage>80</lpage>
        <pub-id pub-id-type="doi">10.1530/EJE-15-0930</pub-id>
        <?supplied-pmid 26671977?>
        <pub-id pub-id-type="pmid">26671977</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Al-Marrawi</surname>
            <given-names>MY</given-names>
          </name>
          <name>
            <surname>Saroya</surname>
            <given-names>BS</given-names>
          </name>
          <name>
            <surname>Brennan</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Dykes</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>El-Deiry</surname>
            <given-names>WS</given-names>
          </name>
        </person-group>
        <article-title>Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer</article-title>
        <source>Cancer Biol Ther</source>
        <year>2013</year>
        <volume>14</volume>
        <issue>8</issue>
        <fpage>703</fpage>
        <lpage>10</lpage>
        <pub-id pub-id-type="doi">10.4161/cbt.25191</pub-id>
        <?supplied-pmid 23792568?>
        <pub-id pub-id-type="pmid">23792568</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Moreira</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Peixoto</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>de Sousa Cruz</surname>
            <given-names>MR</given-names>
          </name>
        </person-group>
        <article-title>Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification</article-title>
        <source>Case Rep Oncol</source>
        <year>2015</year>
        <volume>8</volume>
        <issue>1</issue>
        <fpage>83</fpage>
        <lpage>7</lpage>
        <pub-id pub-id-type="doi">10.1159/000375483</pub-id>
        <?supplied-pmid 25848357?>
        <pub-id pub-id-type="pmid">25848357</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chin</surname>
            <given-names>YR</given-names>
          </name>
          <name>
            <surname>Yoshida</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Marusyk</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Beck</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Polyak</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Toker</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Targeting Akt3 signaling in triple-negative breast cancer</article-title>
        <source>Cancer Res</source>
        <year>2014</year>
        <volume>74</volume>
        <issue>3</issue>
        <fpage>964</fpage>
        <lpage>73</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2175</pub-id>
        <?supplied-pmid 24335962?>
        <pub-id pub-id-type="pmid">24335962</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>JY</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>JC</given-names>
          </name>
          <name>
            <surname>Hou</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>HW</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HW</given-names>
          </name>
        </person-group>
        <article-title>Alternative splicing for diseases, cancers, drugs, and databases</article-title>
        <source>Sci World J</source>
        <year>2013</year>
        <volume>2013</volume>
        <fpage>703568</fpage>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Greenman</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Stephens</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Dalgliesh</surname>
            <given-names>GL</given-names>
          </name>
          <name>
            <surname>Hunter</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Bignell</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Davies</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Teague</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Butler</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Stevens</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Edkins</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>O’Meara</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vastrik</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Schmidt</surname>
            <given-names>EE</given-names>
          </name>
          <name>
            <surname>Avis</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Barthorpe</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bhamra</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Buck</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Choudhury</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Clements</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cole</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dicks</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Forbes</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Gray</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Halliday</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Harrison</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hills</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hinton</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Jenkinson</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Jones</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Menzies</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Mironenko</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Perry</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Raine</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Richardson</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Shepherd</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Small</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Tofts</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Varian</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Webb</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>West</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Widaa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yates</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cahill</surname>
            <given-names>DP</given-names>
          </name>
          <name>
            <surname>Louis</surname>
            <given-names>DN</given-names>
          </name>
          <name>
            <surname>Goldstraw</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Nicholson</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>Brasseur</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Looijenga</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Weber</surname>
            <given-names>BL</given-names>
          </name>
          <name>
            <surname>Chiew</surname>
            <given-names>YE</given-names>
          </name>
          <name>
            <surname>DeFazio</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Greaves</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>AR</given-names>
          </name>
          <name>
            <surname>Campbell</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Birney</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Easton</surname>
            <given-names>DF</given-names>
          </name>
          <name>
            <surname>Chenevix-Trench</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Khoo</surname>
            <given-names>SK</given-names>
          </name>
          <name>
            <surname>Teh</surname>
            <given-names>BT</given-names>
          </name>
          <name>
            <surname>Yuen</surname>
            <given-names>ST</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>SY</given-names>
          </name>
          <name>
            <surname>Wooster</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Futreal</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Stratton</surname>
            <given-names>MR</given-names>
          </name>
        </person-group>
        <article-title>Patterns of somatic mutation in human cancer genomes</article-title>
        <source>Nature</source>
        <year>2007</year>
        <volume>446</volume>
        <issue>7132</issue>
        <fpage>153</fpage>
        <lpage>8</lpage>
        <pub-id pub-id-type="doi">10.1038/nature05610</pub-id>
        <?supplied-pmid 17344846?>
        <pub-id pub-id-type="pmid">17344846</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
